hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06362031, orgStudyIdInfo id: H18.Oncology.12-SR1812, briefTitle: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: AbbVie, class: INDUSTRY, descriptionModule briefSummary: Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with AML receiving venetoclax.Data from up to 700 participants will be collected. No participants will be enrolled in this study.Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 10 months.There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 10 months., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Overall Survival (OS), primaryOutcomes measure: Event-free survival (EFS), primaryOutcomes measure: Percentage of Participants Achieving Best Overall Response, primaryOutcomes measure: Duration of Response (DoR), primaryOutcomes measure: Percentage of Participants with Transfusion Independence (TI), secondaryOutcomes measure: Number of Participants with Healthcare Resource Utilization (HRU), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 89 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362018, orgStudyIdInfo id: MHC/CT/23-24/055, secondaryIdInfos id: MHC/CT/23-24/055, Version No.:, type: OTHER, domain: Mprex Healthcare Pvt. Ltd., briefTitle: Bioavailability of Three Mitopure Formulations, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Amazentis SA, class: INDUSTRY, collaborators name: Mprex Healthcare Pvt. Ltd., descriptionModule briefSummary: This study's design as an open-label, single-dose, randomized trial that aligns with the objective of characterizing the concentration-time profiles of three Urolithin A (Mitopure) formulations in a controlled setting. The inclusion criteria, stringent fasting requirements, standardized fluid intake and strict dietary restriction protocols ensure homogeneity among the study participants, enhancing the reliability of the outcomes.Ultimately, this clinical trial aims to contribute valuable insights into the pharmacokinetic behavior of the different Urolithin A formulations, facilitating informed decisions for future developments and applications in the realm of health and wellness., conditionsModule conditions: Healthy Adults, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Mitopure (Urolithin A), outcomesModule primaryOutcomes measure: Plasma concentrations of Urolithin A over time and maximal plasma concentration (Cmax), primaryOutcomes measure: Exposure to Urolithin A over time measured as area under the curve (AUC), secondaryOutcomes measure: Number of adverse events and serious adverse events throughout the study., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Lokmanya Medical Research Centre and Hospital, city: Pune, zip: 411033, country: India, contacts name: Dr Ramshyam Agarwal, MD, role: CONTACT, geoPoint lat: 18.51957, lon: 73.85535, hasResults: False
protocolSection identificationModule nctId: NCT06362005, orgStudyIdInfo id: AUAREC2023011-1, briefTitle: The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus, acronym: RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, collaborators name: Sphinx university, descriptionModule briefSummary: evaluate clinically and biochemically the efficacy of topically applied selenium as complementary or alternative to triamcinolone acetonide 0.1% and tacrolimus 0.1% in patients with oral lichen planus., conditionsModule conditions: Lichen Planus, Oral, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Triamcinolone Acetonide 0.1% Oint, interventions name: Tacrollimus Topical, interventions name: Selenium, interventions name: Selenium & Triamcinolone Acetonide 0.1% Oint, interventions name: Selenium& Tacrollimus topical, outcomesModule primaryOutcomes measure: to assess a visual analog scale (VAS)of the oral lichen planus lesion, secondaryOutcomes measure: to assess The associated Oral Disease Severity Score 3- Glutathione biomarker level as an antioxidant enzyme in saliva by ELISA analysis, secondaryOutcomes measure: Biochemical evaluation of salivary Glutathione level using (ELISA), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Alazhar university ,faculty of Dental Medicine, city: Assiut, zip: 0000, country: Egypt, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06361992, orgStudyIdInfo id: BC_SERBIA_2022, briefTitle: Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-03-15, primaryCompletionDateStruct date: 2023-09-15, completionDateStruct date: 2024-02-13, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Catalysis SL, class: INDUSTRY, descriptionModule briefSummary: To verify the efficacy and tolerability of Activated Piroctone Olamine (Blue Cap Foam, label volume 100 ml) by CATALYSIS, S. L. Madrid, applied in the management of all types of dermatitis (atopic, seborrheic, eczema) in patients with significant manifestations of the disease in varying areas of the body of varying extent and to assess differences in individual tolerability and the final effect in a group of selected patients aged 3 to 18 years., conditionsModule conditions: Atopic Dermatitis, conditions: Atopic Dermatitis and Related Conditions, conditions: Atopic Dermatitis Eczema, conditions: Atopic Dermatitis \(AD\), designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 58, type: ACTUAL, armsInterventionsModule interventions name: Blue Cap Foam, outcomesModule primaryOutcomes measure: Grade of Patient Tolerability to the investigation product, primaryOutcomes measure: Clinical Improvement of Patients with Dermatitis, primaryOutcomes measure: Clinical assessment of symptoms and sings associated with Dermatitis, secondaryOutcomes measure: Evaluation of the therapeutic effect of Blue Cap in paediatric patients with dermatitis., secondaryOutcomes measure: Evaluation of the therapeutic effect of Blue Cap on healing of the skin at the patients, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: University of Niš Faculty of Medicine, Department of Dermatology and Venereology, University Clinical Center of Niš, city: Niš, state: Nišava, zip: 18108, country: Serbia, geoPoint lat: 43.32472, lon: 21.90333, locations facility: City Institute for Skin and Venereal Diseases Belgrade, city: Belgrade, zip: 11000, country: Serbia, geoPoint lat: 44.80401, lon: 20.46513, locations facility: University of Belgrade Faculty of Medicine, University Clinical Center of Serbia, city: Belgrade, zip: 11000, country: Serbia, geoPoint lat: 44.80401, lon: 20.46513, hasResults: False
protocolSection identificationModule nctId: NCT06361979, orgStudyIdInfo id: A1811, briefTitle: SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Huihua Xiong, class: OTHER, descriptionModule briefSummary: This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases, conditionsModule conditions: Breasr Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: SHR-A1811, interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: CNS-ORR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: ORR, secondaryOutcomes measure: AE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06361966, orgStudyIdInfo id: 2021/00638, briefTitle: Evaluating User Satisfaction and Feasibility of a Remote Model for 3d Scanned and Printed Transtibial Prosthetic Sockets, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-11, primaryCompletionDateStruct date: 2023-01-09, completionDateStruct date: 2023-01-09, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Tan Tock Seng Hospital, class: OTHER, collaborators name: Prosfit Technologies JSC, collaborators name: Centre for Allied Health and Pharmacy Excellence (CAPE), descriptionModule briefSummary: The goal of this clinical trial is to investigate the repeatability of application of a fully remote method of manufacturing 3D printing of prosthetic sockets for transtibial amputees, and determine user satisfaction of sockets produced through these methods. The study also aims to evaluate the time and cost effectiveness of this production model.The main question\[s\] it aims to answer are:1. To determine the repeatability and user satisfaction with transtibial sockets produced using a remote-digital method as compared to conventional manufacturing methods.2. To determine if transtibial prosthetic users have greater prosthetic satisfaction scores across the 4 Prosthesis Evaluation Questionnaire (PEQ) subscales of Utility (UT), Appearance (AP), Sounds (SO) and Residual Limb Health (RL) with the 3D printed socket fabricated through the remote-digital method compared to the laminate socket made using the conventional method.3. To determine if transtibial prosthetic users experience greater socket comfort with the 3D printed socket compared to the laminate socket.Participants will receive a 3D printed socket (trial intervention) and a laminate socket (control intervention) and will use each socket for a period of 4 weeks.The order of socket use will be randomised. At the end of each 4 week period, participants will rate their comfort and satisfaction with the socket. At the end of the trial, participants will indicate their preferred socket, which will be fitted to their prosthesis.Participants will attend 6 visits across a total duration of 11 weeks during the course of the study., conditionsModule conditions: Amputation, conditions: Prosthesis User, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 16, type: ACTUAL, armsInterventionsModule interventions name: 3d printed prosthetic socket, outcomesModule primaryOutcomes measure: Prosthesis Evaluation Questionnaire, primaryOutcomes measure: Socket Comfort Score, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tan Tock Seng Hospital, city: Singapore, zip: 308433, country: Singapore, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06361953, orgStudyIdInfo id: IR.SBMU.MSP.REC. 1401. 161, briefTitle: Comparing the Efficacy of Two Neurofeedback Protocols for Generalized Anxiety Disorder, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2023-07-01, completionDateStruct date: 2023-07-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Shahid Beheshti University of Medical Sciences, class: OTHER, descriptionModule briefSummary: Generalized anxiety disorder (GAD) is one of the most prevalent mental disorders in adults, marked by excessive and uncontrollable worry about various events or activities. It is accompanied by symptoms such as restlessness, irritability, fatigue, difficulty concentrating, problems with sleep, and somatic symptoms.In addition, a critical and up-to-date comparison of different treatments for GAD is crucial due to their high costs and unsatisfactory outcomes. EEG neurofeedback training has not reached the same level of evidence as more extensively validated non-pharmacological treatments, such as cognitive behavioral therapy.This study aimed to compare the efficacy of two protocols: one targeting alpha-theta amplitude increase and the other concentrating on SMR., conditionsModule conditions: Generalized Anxiety Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: EEG Neurofeedback, outcomesModule primaryOutcomes measure: The Beck Anxiety Inventory, primaryOutcomes measure: The Perceived Stress Questionnaire, primaryOutcomes measure: Spielberger's state-trait anxiety test, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shahid Beheshti University of Medical Science, city: Tehran, zip: 4739-19395, country: Iran, Islamic Republic of, geoPoint lat: 35.69439, lon: 51.42151, hasResults: False
protocolSection identificationModule nctId: NCT06361940, orgStudyIdInfo id: IIT-CHAUDHARY-ENDOCRINE2-OPP, briefTitle: Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2029-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Medical College of Wisconsin, class: OTHER, descriptionModule briefSummary: This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks)., conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Aromatase inhibitors or tamoxifen, outcomesModule primaryOutcomes measure: Change from baseline in the number of subjects with increased HER-1 receptor tyrosine kinases protein expression in tumors., primaryOutcomes measure: Change from baseline in the number of subjects with increased HER-2 receptor tyrosine kinases protein expression in tumors., primaryOutcomes measure: Change from baseline in the number of subjects with increased HER-3 receptor tyrosine kinases protein expression in tumors., primaryOutcomes measure: Change from baseline in the number of subjects with increased HER-4 receptor tyrosine kinases protein expression in tumors., eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Froedtert Hospital and the Medical College of Wisconsin, city: Milwaukee, state: Wisconsin, zip: 53226, country: United States, contacts name: Lubna N Chaudhary, MD, role: CONTACT, email: lchaudhary@mcw.edu, geoPoint lat: 43.0389, lon: -87.90647, hasResults: False
protocolSection identificationModule nctId: NCT06361927, orgStudyIdInfo id: SSGJ-707-NSCLC-II-01, briefTitle: A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC., conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: SSGJ-707, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: Safety and tolerability, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Hunan Cancer Hospital, status: RECRUITING, city: Changsha, state: Hunan, country: China, contacts name: Lin Wu, MD,Ph.D, role: CONTACT, phone: 0731-89762302, email: wulin-calf@vip.163.com, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06361901, orgStudyIdInfo id: 2023GR0452, briefTitle: Comparison of Therapeutic Effect Between Speech Rehabilitation Program and Speech Therapy in Stroke Patients With Aphasia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-17, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Korea University Guro Hospital, class: OTHER, descriptionModule briefSummary: Our study will provide precise and intensive speech rehabilitation treatment program to patients with speech disorders after stroke, and compare clinical evaluations with the conventional speech therapy patient group.Clinical evaluation tools will be performed before and after the treatment for all patients* K-Western Aphasia Battery for aphasia assessment tools* Cerebral blood flow changes with near-infrared spectroscopy, conditionsModule conditions: Stroke, conditions: Aphasia, conditions: Speech Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Zenicog;language rehabilitation program, interventions name: Conventional language rehabilitation, outcomesModule primaryOutcomes measure: Aphasic quatient, secondaryOutcomes measure: Change of cerebral blood flow, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Rehabilitation Medicine, Korea University Guro Hospital, status: RECRUITING, city: Seoul, zip: 08308, country: Korea, Republic of, contacts name: Seung Nam Yang, MD, PhD, role: CONTACT, phone: 82-2-2626-1500, email: snamyang@korea.ac.kr, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06361888, orgStudyIdInfo id: 2023-012-00CH1, briefTitle: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2027-08-31, completionDateStruct date: 2027-08-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Hutchmed, class: INDUSTRY, descriptionModule briefSummary: To evaluate the efficacy of Surufatnib combined withcamrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer, conditionsModule conditions: Metastatic Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 482, type: ESTIMATED, armsInterventionsModule interventions name: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, interventions name: Nab-paclitaxel Plus Gemcitabine, interventions name: Surufatinib with Nab-paclitaxel, and Gemcitabine, outcomesModule primaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Progression-free Survival (PFS) (RECIST1.1), secondaryOutcomes measure: Objective response rate (ORR)(RECIST1.1), secondaryOutcomes measure: Duration of response (DoR)(RECIST1.1), secondaryOutcomes measure: Disease control rate (DCR)(RECIST1.1), secondaryOutcomes measure: Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30), secondaryOutcomes measure: Cancer Quality of Life Questionnaire - PAN26(EORTC QLQ-PAN26), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanjing Tianyinshan Hospital, city: Nanjing, state: Jiang Su, zip: 210000, country: China, contacts name: Shukui Qin, Prof., role: CONTACT, geoPoint lat: 32.06167, lon: 118.77778, locations facility: Tianjin Cancer Hospital, city: Tianjin, state: Tianjin, zip: 300000, country: China, contacts name: Jihui Hao, Prof., role: CONTACT, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False